Topic Collection Search
Allergy and immunology
Complementary medicine and alternative therapies
Critical care / intensive care
Dentistry / oral medicine
Geriatric medicine / aging
Haematology / blood transfusion
History of medicine
Legal and forensic medicine
Nutrition and metabolism
Obstetrics and gynaecology
Occupational and environmental medicine
Organisation of health care
Otolaryngology / head and neck surgery
Pharmacology and therapeutics
Primary care, family medicine
Psychiatry and psychotherapy
Quality of care
Statistics and research methods
Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab
Based on the available literature and the experiences collected from adult and paediatric patients treated in Switzerland, the Working Party on Haemostasis of the Swiss Society of Haematology and the Swiss Haemophilia Network provides a practical guidance for the management of breakthrough bleeding events and surgery in patients with haemophilia A without inhibitors treated with emicizumab.
These are the Swiss Amyloidosis Network recommendations which focus on diagnostic work-up and treatment of AL-amyloidosis. One aim of this meeting was to establish a consensus guideline regarding the diagnostic work-up and the treatment recommendations for systemic amyloidosis tailored to the Swiss health care system.
Venous thromboembolism very commonly complicates the clinical course of inpatients with COVID-19, despite thromboprophylaxis. The risk appears highest among critically ill inpatients. Many questions remain unresolved, as delineated by the heterogeneity of national and international guidelines.
Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland
Management of acute heparin-induced thrombocytopenia currently involves cessation of heparin exposure, and inhibition of coagulation with an anticoagulant other than heparin.
Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis
Based on the available literature and published recommendations from international societies, the Working Party on Hemostasis (Swiss Society of Hematology) has prepared recommendations for pharmacological thromboprophylaxis in COVID-19 patients in the acute setting.
“Liquid biopsy” in lymphoma types lacking leukaemic involvement refers to the accessing of tumour-specific DNA in plasma, serum or other body fluids, without the necessity of an invasive tumour biopsy.
The occurrence and development of cancer cells in the body is a dynamic process of interaction between the immune system and the tumour cells. Whether tumour growth is promoted or suppressed in the parabiosis model is still unclear.
Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life.
Diffuse large B-cell lymphoma chemotherapy reveals a combined immunodeficiency syndrome in cartilage hair hypoplasia
Cartilage hair hypoplasia is a rare autosomal recessive ribosomopathy related to a mutation in the ribonuclease mitochondrial RNA processing (RMRP) gene, which encodes the mitochondrial portion of the RNA processing endonuclease.